|
WO2021035170A1
|
|
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2021035054A1
|
|
Lymphodepletion dosing regimens for cellular immunotherapies
|
|
WO2021016608A1
|
|
Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
|
|
WO2020227534A1
|
|
Optimization of engineered meganucleases for recognition sequences
|
|
WO2020206231A1
|
|
Methods of preparing populations of genetically-modified immune cells
|
|
WO2020206248A1
|
|
Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
|
|
WO2020146807A1
|
|
Genetically-modified cells comprising a modified transferrin gene
|
|
WO2020132659A1
|
|
Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
|
|
KR20200142037A
|
|
Optimized engineered nuclease with specificity for human T cell receptor alpha constant region genes
|
|
US2019338263A1
|
|
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
|
US2020299658A1
|
|
Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
|
|
US2020239544A1
|
|
Modified epidermal growth factor receptor peptides for use in genetically-modified cells
|
|
WO2019005957A1
|
|
Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
|
|
WO2018208837A1
|
|
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
|
|
US2020190541A1
|
|
Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells
|
|
US2020131489A1
|
|
Engineered meganucleases specific for recognition sequences in the pcsk9 gene
|
|
BR112019007450A2
|
|
modified meganucleases specific for recognition sequences in the hepatitis b virus genome
|
|
CA3022801A1
|
|
Engineered nucleases useful for treatment of hemophilia a
|
|
WO2017112859A1
|
|
Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
|
|
CN108601821A
|
|
Include the genetically modified cell of modified human T cell receptor α constant region genes
|
